Skip to main content

Tissue microarray-based immunohistochemical study can significantly underestimate the expression of HER2 and progesterone receptor in ductal carcinoma in situ of the breast.

Lin Y, Hatem J, Wang J, Quinn A, Hicks D, Tang P

Publication: Biotech Histochem (2011) • Vol 86 • Page 345-50PMID: 20701550View on PubMed

Purpose

The purpose of this paper was to compare estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) immunohistochemical (IHC) staining of tissue microarrays (TMA) and whole sections of breast cancer tissue.

Conclusion

The specificity and sensitivity rates of TMA-based ER IHC were 87.0 and 90.4%, respectively when whole sections were used as the reference. For PR and HER2, the specificity and sensitivity rates were 75.9 and 76.1% and 90.6 and 27.3%, respectively. When the number of TMA cores evaluated increased, non-concordance rates between TMA and whole sections decreased. Tumor size had no effects on non-concordance rates between TMA and whole sections.

Studies (1)

Purpose

The purpose of this study was to compare ER, PR, and HER2 IHC staining of TMA with staining seen in whole sections of ductal carcinoma in situ of the breast. Concordance rates between the two types of slides were evaluated with respect to core number on the TMA. The authors defined positive TMA results as staining in at least 1 of 3 cores.

Summary of Findings

The specificity and sensitivity rates of TMA-based ER IHC were 87.0 and 90.4%, respectively when whole sections were used as the reference. For PR and HER2, the specificity and sensitivity rates were 75.9 and 76.1% and 90.6 and 27.3%, respectively. When the number of TMA cores evaluated was increased from 1 to 2 and 3, non-concordance rates (including discordance and non-informative results) between TMA and whole sections decreased from 46.5% to 22.7% and 11.6%, respectively (p<0.001). Tumor size had no effects on non-concordance rates between TMA and whole sections which were 33.3%, 37.1%, and 39.3% for tumor sizes < 1 cM, 1-2 cM, and > 2 cM, respectively.
  • Biospecimens

    TissueBreast
  • Preservation Types

    Formalin
  • Diagnoses

    NeoplasticCarcinoma
  • Platforms

    ProteinImmunohistochemistry
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    Biospecimen Aliquots and ComponentsAliquot size/volume
    1 TMA core
    1-2 cM tumor size
    2 TMA cores
    3 TMA cores
    < 1 cM tumor size
    > 2 cM tumor size
    Biospecimen Aliquots and ComponentsType of slide
    TMA
    Whole section
    Immunohistochemistry SpecificTargeted peptide/protein
    ER
    HER2
    PR